AbbVie is a Dividend King with a bright future.
Enbridge offers an especially dependable dividend.
Realty Income has a juicy dividend yield and a great growth opportunity in Europe.
Sit back, and let the money roll in. That's the idea with passive income. Unfortunately, it's not always that easy. Sometimes, investments that initially look promising turn out to be duds after a while.
However, some alternatives pay you consistently and reliably over the long run. Want decades of passive income? Here are three stocks to buy now and hold forever.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
You won't find stocks that pay more dependable dividends than the elite group known as Dividend Kings. These stocks have increased their dividends for at least 50 consecutive years. And AbbVie (NYSE: ABBV) is a member in good standing, with its 53 straight years of dividend hikes (including the time it was part of Abbott Labs (NYSE: ABT)).
AbbVie's forward dividend yield is currently a hair below 3%. This yield is on the low end of the drugmaker's historical range, but for a good reason: The pharma stock has been a big winner in recent years and is up more than 30% in 2025.
What's behind this success? AbbVie has done a phenomenal job in navigating what could have been a devastating patent cliff. The company's longtime top-selling drug, Humira, lost U.S. patent exclusivity in 2023. But AbbVie's investments in research and development and strategic acquisitions paid off. The company now has multiple products that have reduced its dependence on Humira.
The future looks bright for this big drugmaker, too. Sales for Humira's two successors, Rinvoq and Skyrizi, are skyrocketing. It's a similar story for AbbVie's migraine therapies, Qulipta and Ubrelvy. To add icing to the cake, AbbVie's pipeline is promising, with around 50 programs in mid- and late-stage clinical development.
While Enbridge (NYSE: ENB) isn't a Dividend King, its dividend track record is nonetheless impressive. This energy company has increased its dividend for 30 consecutive years. That makes Enbridge a member of the Dividend Champions -- companies with at least 25 consecutive years.
Enbridge's forward dividend yield is a hefty 5.5%. Investors seeking passive income should have nothing to worry about with this high yield. Enbridge generates ample free cash flow to cover its dividend payments.
The nature of Enbridge's business makes the company's dividend especially dependable. Enbridge ranks as the largest natural gas utility in North America based on volume. Its pipelines transport around one-fifth of the natural gas consumed in the U.S. and 30% of the total crude oil produced in North America. Roughly 80% of Enbridge's earnings before interest, taxes, depreciation, and amortization (EBITDA) is protected against inflation, with less than 1% of EBITDA exposed to volatile commodity prices.
Although Enbridge probably won't generate jaw-dropping growth going forward, it shouldn't be stagnant. The increasing number of power-hungry data centers and conversions of power plants from coal to natural gas bode well for the company's growth prospects.
Like Enbridge, Realty Income (NYSE: O) is a Dividend Champion with 30 consecutive years of dividend increases. This real estate investment trust (REIT) also pays its dividend monthly rather than quarterly.
Want even better news? Realty Income's forward dividend yield is 5.7%. Such high yields aren't unusual for REITs, because they must return at least 90% of income to shareholders as dividends to be exempt from federal income taxes.
Passive income investors should really like Realty Income's stability. The REIT has delivered 29 straight years of positive total operational returns (the sum of annual adjusted funds from operations per share growth and dividend yield). This impressive performance is a direct result of Realty Income's strong and well-diversified property portfolio.
Realty Income has pretty good growth opportunities as well. The company's total addressable market is around $14 trillion. Europe has an especially attractive market with fragmented competition.
Before you buy stock in AbbVie, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $622,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,145,426!*
Now, it’s worth noting Stock Advisor’s total average return is 1,046% — a market-crushing outperformance compared to 191% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of November 10, 2025
Keith Speights has positions in AbbVie, Enbridge, and Realty Income. The Motley Fool has positions in and recommends AbbVie, Abbott Laboratories, Enbridge, and Realty Income. The Motley Fool has a disclosure policy.